Dantoing, E.; Demontrond, P.; Léturgie, B.; Curcio, H.; Orsini, C.; Coquard, A.; Tillon-Strozyk, J.; Gervais, R.; Thiberville, L.; Bota, S.; Guisier, F. Real-World Efficacy and Safety of Paclitaxel-Gemcitabine in Relapsed Small-Cell Lung Cancer. Preprints2024, 2024050845. https://doi.org/10.20944/preprints202405.0845.v1
APA Style
Dantoing, E., Demontrond, P., Léturgie, B., Curcio, H., Orsini, C., Coquard, A., Tillon-Strozyk, J., Gervais, R., Thiberville, L., Bota, S., & Guisier, F. (2024). Real-World Efficacy and Safety of Paclitaxel-Gemcitabine in Relapsed Small-Cell Lung Cancer. Preprints. https://doi.org/10.20944/preprints202405.0845.v1
Chicago/Turabian Style
Dantoing, E., Suzanna Bota and Florian Guisier. 2024 "Real-World Efficacy and Safety of Paclitaxel-Gemcitabine in Relapsed Small-Cell Lung Cancer" Preprints. https://doi.org/10.20944/preprints202405.0845.v1
Abstract
Small-cell lung cancer (SCLC) is a cancer with poor prognosis. For relapsed extensive-stage (ES) SCLC, second-line treatment options are scarce. Topotecan was the only approved treatment in this setting until 2020. Since topotecan induces significant toxicities, alternative off-label regimens are being used. This study evaluated real-world efficacy and safety of Paclitaxel Gemcitabine chemotherapy in patients with relapsed ES-SCLC. We retrospectively reviewed data from all consecutive patients with relapsed ES-SCLC who received Paclitaxel Gemcitabine chemotherapy from september 2008 to january 2022 in two centers. Patient characteristics (n=188) were: PS≥2: 24.5%; brain metastasis: 42%; platinum-sensitive disease: 41%. Patients received Paclitaxel Gemcitabine as second- (77%) third (18%) or fourth (6%) line of therapy. Median progression-free and overall survival were 2.1 (95CI 1.8–2.4) and 3.8 (95CI 3.3–4.8) months in the overall population, respectively, with 17% response rate (RR) and 28% disease-control rate. PS, history of brain radiation, platinum-sensitive disease, liver, and adrenal gland metastasis were associated with longer survival in univariate analysis. PS was the only prognostic factor in multivariate analysis, with 21% RR and 4.1 months median DOR in PS 0-1 patients.
Paclitaxel Gemcitabine chemotherapy may represent a treatment option in PS0-1 relapsed SCLC.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
,
,
,
,
*
